{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070448","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.712648+00:00","generated_at":"2026-05-21T17:03:08.388476+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Metagenomi NHP hemophilia A study shows durable FVIII activity through 19 months; Q1 cash $226M","bullets":["Hemophilia A NHP study: durable FVIII activity at therapeutically relevant levels through ~19 months; final FVIII levels 80%, 10%, 32%.","Cash, equivalents, and marketable securities $226.0M as of Mar 31, 2025; runway into 2027.","R&D expenses $25.1M (Q1 2025) vs $31.4M (Q1 2024); G&A $6.8M vs $8.8M.","Published novel compact CRISPR-associated transposases in Nature Communications."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070448","json":"https://secwatch.observer/filing/0000950170-25-070448.json","markdown":"https://secwatch.observer/filing/0000950170-25-070448.md","text":"https://secwatch.observer/filing/0000950170-25-070448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025070448/0000950170-25-070448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025070448/mgx-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:03:08.388476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}